INSIGHTS ON DRUG DEVELOPMENT
-
Improving The Efficiency And Quality Of Advanced Imaging And Analysis
Human-relevant models are transforming drug screening. Find out how overcoming 3D cell culture challenges with integrated innovations accelerates discovery and brings effective treatments to patients faster.
-
Inside Asymchem's Advanced R&D Capabilities In The UK
Advanced experimentation, unified workflows, and continuous manufacturing are accelerating small‑molecule development, improving insight and creating more efficient paths from discovery to scale.
-
Immuno-Oncology Biomarker Measurement With High Sensitivity And Speed
Explore results demonstrating the successful use of innovative ELISA assays to detect three key biomarkers: Programmed Death Ligand 1 (PD-L1), Interleukin-8 (IL-8), and Interferon Gamma (IFN-γ).
-
Grace Capabilities Update February 2026: AI Drug Development
Discover support for your next small molecule drug substance program and learn how artificial intelligence and machine learning tools can be applied to accelerate API development.
-
Softgel Formulation Strategies For Challenging Oral Compounds6/19/2026
Explore strategies to solve solubility and permeability challenges, boost oral bioavailability, and ensure consistent absorption — reducing risk and unlocking complex molecules.
-
Take Action On PFAS To Protect Your Critical Processes9/18/2025
PFAS restrictions are tightening, but a full ban could disrupt critical industries lacking alternatives, such as pharmaceutical manufacturing. Learn where PFAS use remains indispensable.
-
Rapid Walkaway Solution For Assessing Viability In Cancer Organoids3/31/2025
Assess anti-cancer compounds' effects on organoid size and morphology with colorectal cancer organoids as well as discover automated imaging and viability assays to streamline drug screening and aid early identification.
-
Accelerate FDA Approval With Fast Track Designation7/3/2025
Learn how Fast Track Designation streamlines the FDA review process and offers faster approval for serious diseases or life-threatening conditions.
-
Why Emerging Drug Developers Can't Afford To Delay Analytical Development5/21/2026
Rushing early pharma development by neglecting quality and analytical frameworks risks regulatory failures, clinical holds, and expensive rework.
DRUG DEVELOPMENT SOLUTIONS
-
Explore an expansion service with experts that will work closely with you to customize your process and meet your unique needs by adjusting protocols, optimizing conditions, and providing personalized support.
-
Discover purpose-built lab tools that combine intuitive design, dependable performance, and accessible cost to support fast, confident scientific work.
-
Examine how sterilizing-grade filters with high flux and broad compatibility support efficient bioprocessing across mAbs, vaccines, and viral vectors.
-
Gene therapies hold immense potential to provide long-lasting treatments for a wide range of diseases. At Cytiva, we offer GMP-compliant, end-to-end manufacturing solutions designed to support the development and commercialization of advanced medicines across multiple modalities – including AAV, adenovirus (AV), lentivirus (LV), plasmid DNA (pDNA) and exosomes. Our dependable suite of technologies and expertise ensures scalability, quality, and regulatory confidence at every stage of your journey.
-
Routine cell culture? Check!
For researchers who need consistent experimental outcomes, Mateo TL enables all lab members to check and document cell growth status conveniently and comfortably.
Measure confluency consistently, thereby increasing the confidence in the success of their downstream experiments.